S-Ventures to Present at Aquis Showcase Event

S-Ventures PLC
24 November 2023
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION, AS PERMITTED BY UK MAR. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.

S-Ventures PLC

("S-Ventures" or the "Group")

S-Ventures to Present at The VSA Aquis Showcase Event

S-Ventures (AQSE: SVEN), the company investing in brands across the natural, wellness and food-tech categories, is pleased to announce it will be presenting at 'Britain's Got Aquis', The VSA Aquis Showcase Event on Tuesday, 28 November 2023 at the Royal College of Surgeons, London.

Scott Livingston, the Company's CEO, will present to attendees between 12:20pm and 13:10pm. Management will be available throughout the day to engage with investors.  

The VSA Aquis Showcase Event is a one-day event with companies presenting and competing in an investment contest, to be judged by Schroders' Head of Pan European Small and Mid-Cap Fund, Andy Brough.

Existing and potential shareholders are encouraged to attend the event and watch the presentation. Limited tickets remain for this event. For further information on the event and purchase tickets, please visit: VSA Aquis Showcase Event.

For further information, please contact:

 

S-Ventures plc

Scott Livingston (Chief Executive Officer)

+44 (0) 1932 400 224

Stephen Argent (Chief Financial Officer)





VSA Capital, AQSE Corporate Adviser and Broker:

Andrew Raca

Matt Harker

 

+44 (0) 20 3005 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100